Here are the 10-K annual reports from Drugs Made In America Acquisition II Corp. Unit (DMIIU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DMIIU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMIIU filings page.
Drugs Made In America Acquisition II Corp. is a Cayman Islands-based blank check company focused on acquiring a pharmaceutical business. It completed an IPO of 50,000,000 units at $10.00 each, placing $500,000,000 in a trust account invested in short-term U.S. Treasuries.
The sponsor and Cantor also bought 1,200,000 private units for $12,000,000. The company has no operations or revenue and reported 2025 net income of $4,187,050, driven mainly by interest on trust investments and a gain on extinguishment of an over-allotment option liability.
Working capital is tight, with only $223 of cash and a working capital deficit of $274,827 as of December 31, 2025, leading to substantial doubt about its ability to continue as a going concern. Between September 26 and December 31, 2025, the sponsor withdrew $1,345,844 from the working capital account, leaving $812,113 due back, which the company fully reserved as a current expected credit loss.
After the sponsor indicated it could not repay this balance, the board accepted the resignation of former CEO and executive chair Lynn Stockwell in February 2026 and appointed Roger Bendelac as CEO. The company later arranged up to $1,400,000 of convertible note financing, including a $150,000 bridge note and a $300,000 interim note, to fund transaction and operating costs while it seeks a business combination within 24 months of the IPO closing.